Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire Sells 160,400 Shares

Invivyd, Inc. (NASDAQ:IVVD) Director Terrance Mcguire sold 160,400 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $0.59, for a total value of $94,636.00. Following the completion of the transaction, the director now directly owns 4,202,679 shares in the company, valued at approximately $2,479,580.61. This trade represents a 3.68 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Terrance Mcguire also recently made the following trade(s):

• On Monday, December 9th, Terrance Mcguire sold 150,000 shares of Invivyd stock. The stock was sold at an average price of $0.61, for a total value of $91,500.00.

Invivyd Price Performance

Invivyd stock opened at $0.58 on Thursday. The stock has a market capitalization of $69.86 million, a price-to-earnings ratio of -0.30 and a beta of 0.53. Invivyd, Inc. has a 1-year low of $0.57 and a 1-year high of $5.20. The business has a fifty day moving average price of $0.85 and a 200-day moving average price of $1.08.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on IVVD. HC Wainwright dropped their target price on Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. Morgan Stanley dropped their target price on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. EF Hutton Acquisition Co. I raised Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $9.00 target price on shares of Invivyd in a research report on Thursday, November 21st. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $7.89.

Institutional Trading of Invivyd

A number of institutional investors have recently made changes to their positions in the business. Proficio Capital Partners LLC purchased a new position in Invivyd in the 3rd quarter worth $27,000. SG Americas Securities LLC raised its stake in Invivyd by 198.6% in the 2nd quarter. SG Americas Securities LLC now owns 37,893 shares of the company’s stock worth $42,000 after acquiring an additional 25,201 shares during the last quarter. XTX Topco Ltd raised its stake in Invivyd by 68.1% in the 2nd quarter. XTX Topco Ltd now owns 37,938 shares of the company’s stock worth $42,000 after acquiring an additional 15,376 shares during the last quarter. Cornercap Investment Counsel Inc. purchased a new position in Invivyd in the 2nd quarter worth $86,000. Finally, Rhumbline Advisers raised its stake in Invivyd by 4,434.1% in the 2nd quarter. Rhumbline Advisers now owns 84,017 shares of the company’s stock worth $92,000 after acquiring an additional 82,164 shares during the last quarter. Institutional investors and hedge funds own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.